Журнал биомедицинских и фармацевтических наук

Alterations in Eosinophil Cationic Protein in Asthma and CRSwNP Participants Receiving Dupilumab

Abstract

Matsumoto Yasushi

Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are chronic inflammatory diseases that affect the respiratory and nasal passages, respectively. Both conditions are often characterized by elevated levels of eosinophil, a type of white blood cell that plays a crucial role in the immune response. Eosinophilic inflammation is a key feature of these diseases and is associated with a range of symptoms and complications. Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, inhibiting the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13). Dupilumab has demonstrated remarkable efficacy in treating asthma and CRSwNP, significantly reducing symptoms and improving the quality of life for many patients. This success can be attributed to its ability to reduce eosinophilic inflammation, which leads to alterations in various biomarkers, including Eosinophil Cationic Protein (ECP).